Search

Displaying results 2121 - 2130 of 7687 in total
  1. Drug

    Tirzepatide

    go.drugbank.com/drugs/DB15171
    ApprovedInvestigational

    [A246265] Tirzepatide was approved by the FDA on May 13, 2022, under the brand name MOUNJARO by the FDA for the treatment of adults with type 2 diabetes, making it the first and only GIP and GLP-1 receptor

  2. Drug

    Etuvetidigene Autotemcel

    go.drugbank.com/drugs/DB17593
    ApprovedInvestigational

    [L54698] First approved by the FDA on December 9, 2025, etuvetidigene autotemcel is used to treat Wiskott–Aldrich syndrome (WAS) in selected pediatric and adult patients. … Etuvetidigene autotemcel is an autologous gene therapy which includes hematopoietic stem cells (HSCs) that have been genetically modified ex vivo.

  3. Drug

    Nemolizumab

    go.drugbank.com/drugs/DB15252
    ApprovedInvestigational

    [A264274] It was later approved by the FDA on August 13, 2024, for the treatment of prurigo nodularis.[L51169] … Nemolizumab is a humanized monoclonal modified immunoglobulin 2 (IgG2) antibody directed against interleukin-31 receptor alpha (IL-31RA),[L51159] which is an endogenous cytokine implicated in the pathophysiology

  4. Drug

    Taurolidine

    go.drugbank.com/drugs/DB12473
    ApprovedInvestigational

    Taurolidine is an antimicrobial used for the prevention of catheter-related infections. It is a derivative of the amino acid [taurine]. … [A263217] In November 2023, a catheter lock solution of taurolidine in combination with [heparin] - marketed as Defencath - received FDA approval under the Limited Population Pathway for Antibacterial

  5. Drug

    Foreskin keratinocyte (neonatal)

    go.drugbank.com/drugs/DB10772
    Approved

    Foreskin keratinocytes are an important ingredient in several skin substitutes [L2460], used for various indications. … When an epidermal layer was added, this approach became known as "skin equivalent", "composite culture" or "organotypical culture" [L2453].

  6. Drug

    ALTU-135

    go.drugbank.com/drugs/DB05330
    Investigational

    ALTU-135 has been granted orphan drug and fast-track designation as well as CMA Pilot 2 program status by the Food and Drug Administration (FDA).

  7. Drug

    Zidesamtinib

    go.drugbank.com/drugs/DB21623
    ApprovedInvestigational

    [L63808] The FDA approved zidesamtinib on July 22, 2026, for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer who received a prior ROS1 kinase inhibitor. … another ROS1 inhibitor has failed rather than as an alternative first choice.

  8. Drug

    Docetaxel

    go.drugbank.com/drugs/DB01248
    ApprovedInvestigational

    [L46466] Docetaxel was approved by the FDA in 1996 and is available in solution for injection for intravenous or parenteral administration.[A259676] … [A259676] Compared to paclitaxel, docetaxel is two times more potent as an inhibitor of microtubule depolymerization. Docetaxel binds to microtubules but does not interact with dimeric tubulin.

  9. Drug

    Dobutamine

    go.drugbank.com/drugs/DB00841
    ApprovedInvestigational

    A beta-1 agonist catecholamine that has cardiac stimulant action without evoking vasoconstriction or tachycardia. It is proposed as a cardiotonic after myocardial infarction or open heart surgery.

    Synonyms: DL-dobutamine
  10. Drug

    Ropeginterferon alfa-2b

    go.drugbank.com/drugs/DB15119
    ApprovedInvestigational

    [A242010, A242015] Ropeginterferon alfa-2b was approved by the FDA on November 12, 2021, and is currently marketed under the trademark BESREMi by PharmaEssentia Corporation.[L39170] … Polycythemia vera (PV) is the most common Philadelphia chromosome-negative myeloproliferative neoplasm (MPN), characterized by increased hematocrit and platelet/leukocyte counts, an increased risk for